236 related articles for article (PubMed ID: 18508207)
1. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
Yu E; Miotto K; Akerele E; Montgomery A; Elkashef A; Walsh R; Montoya I; Fischman MW; Collins J; McSherry F; Boardman K; Davies DK; O'Brien CP; Ling W; Kleber H; Herman BH
Drug Alcohol Depend; 2008 Sep; 97(1-2):158-68. PubMed ID: 18508207
[TBL] [Abstract][Full Text] [Related]
2. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
[TBL] [Abstract][Full Text] [Related]
3. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE
J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial.
Fishman M; Tirado C; Alam D; Gullo K; Clinch T; Gorodetzky CW;
J Addict Med; 2019; 13(3):169-176. PubMed ID: 30531234
[TBL] [Abstract][Full Text] [Related]
5. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
Gish EC; Miller JL; Honey BL; Johnson PN
Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
[TBL] [Abstract][Full Text] [Related]
6. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
Walsh SL; Strain EC; Bigelow GE
Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
[TBL] [Abstract][Full Text] [Related]
8. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
Kahn A; Mumford JP; Rogers GA; Beckford H
Drug Alcohol Depend; 1997 Jan; 44(1):57-61. PubMed ID: 9031821
[TBL] [Abstract][Full Text] [Related]
9. Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L; Ali R; White JM
Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
[TBL] [Abstract][Full Text] [Related]
10. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
Kuszmaul AK; Palmer EC; Frederick EK
J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
[TBL] [Abstract][Full Text] [Related]
11. Alpha2-adrenergic agonists in opioid withdrawal.
Gowing LR; Farrell M; Ali RL; White JM
Addiction; 2002 Jan; 97(1):49-58. PubMed ID: 11895270
[TBL] [Abstract][Full Text] [Related]
12. Alpha₂-adrenergic agonists for the management of opioid withdrawal.
Gowing L; Farrell M; Ali R; White JM
Cochrane Database Syst Rev; 2016 May; 2016(5):CD002024. PubMed ID: 27140827
[TBL] [Abstract][Full Text] [Related]
13. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Carnwath T; Hardman J
Drug Alcohol Depend; 1998 May; 50(3):251-4. PubMed ID: 9649979
[TBL] [Abstract][Full Text] [Related]
14. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Haney M; Hart CL; Vosburg SK; Comer SD; Reed SC; Foltin RW
Psychopharmacology (Berl); 2008 Mar; 197(1):157-68. PubMed ID: 18161012
[TBL] [Abstract][Full Text] [Related]
15. A double-blind randomized placebo-controlled trial of lofexidine in alcohol withdrawal: lofexidine is not a useful adjunct to chlordiazepoxide.
Keaney F; Strang J; Gossop M; Marshall EJ; Farrell M; Welch S; Hahn B; Gonzalez A
Alcohol Alcohol; 2001; 36(5):426-30. PubMed ID: 11524309
[TBL] [Abstract][Full Text] [Related]
16. Lofexidine versus clonidine in rapid opiate detoxification.
Gerra G; Zaimovic A; Giusti F; Di Gennaro C; Zambelli U; Gardini S; Delsignore R
J Subst Abuse Treat; 2001 Jul; 21(1):11-7. PubMed ID: 11516922
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
18. Alpha2 adrenergic agonists for the management of opioid withdrawal.
Gowing L; Farrell M; Ali R; White J
Cochrane Database Syst Rev; 2004 Oct; (4):CD002024. PubMed ID: 15495025
[TBL] [Abstract][Full Text] [Related]
19. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal.
Lin SK; Strang J; Su LW; Tsai CJ; Hu WH
Drug Alcohol Depend; 1997 Nov; 48(2):127-33. PubMed ID: 9363412
[TBL] [Abstract][Full Text] [Related]
20. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
Strang J; Bearn J; Gossop M
Am J Addict; 1999; 8(4):337-48. PubMed ID: 10598217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
